GlassScriptPhysician profile
Halston L Hendley
NPI 1942531819
$2,093.03
in general payments reported to CMS, 2019-2025
18 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $35.81 · 2023: $357 · 2024: $367 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $610.05 | 2023-2025 | Erleada, Carvykti, Rybrevant |
| Urogen Pharma, INC. | $353.95 | 2021-2024 | Jelmyto |
| Pfizer INC. | $198.64 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $149.91 | 2023-2025 | Adstiladrin |
| Aveo Pharmaceuticals, INC. | $120.60 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.40 | 2024-2025 | |
| Astellas Pharma US INC | $111.29 | 2023-2025 | Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $82.71 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $79.43 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $74.12 | 2021-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $37.11 | 2023 | Pylarify |
| Immunitybio, INC. | $30.30 | 2025 | |
| Davol INC. | $27.97 | 2025 | |
| Sumitomo Pharma America, INC. | $27.38 | 2024 | Orgovyx |
| Boston Scientific Corporation | $23.51 | 2024 | Ams 700 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $22.29 | 2025 | Prolaris |
| Recordati_rare_diseases_inc. | $16.28 | 2023 | Panhematin |
| Azurity Pharmaceuticals, INC. | $14.09 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halston Hendley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.